From Wikipedia, the free encyclopedia
|AHFS/Drugs.com||Multum Consumer Information|
|Protein binding||>95% (aprepitant)|
|Biological half-life||9 to 13 hours (aprepitant)|
|Chemical and physical data|
|Molar mass||614.406 g/mol|
|3D model (JSmol)|
|(what is this?)|
Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 and by the European Medicines Agency (EMA) on January 11 of the same year.
- "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.
- "European Public Assessment Report for Ivemend (from the EMEA website)". Retrieved 2008-03-15.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|